Liver Cirrhosis Market Report 2025

The liver cirrhosis market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to the rising prevalence of liver diseases, high alcohol consumption, an aging population, higher healthcare expenditure, and growing government initiatives.

The liver cirrhosis market size is expected to see rapid growth in the next few years. It will grow to $2.74 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth during the forecast period can be attributed to the increasing incidence of hepatitis infections, rising economic growth, greater urbanization, lifestyle changes, and the growth of medical tourism. Key trends during this period include advancements in diagnostic tools, technological innovations, collaborations and partnerships, the integration of artificial intelligence, and the incorporation of holistic therapies.

The rising consumption of alcohol is expected to drive the growth of the liver cirrhosis market. Alcohol consumption, typically measured by its quantity and frequency, is increasing as it helps people relax from daily stress, promotes social connections at gatherings, and enhances moments of relaxation. Additionally, alcohol is widely advertised through media and is more accessible in various settings. For patients with excessive alcohol consumption, liver cirrhosis treatment primarily focuses on managing liver damage through abstinence, medications, and supportive care, while addressing alcohol dependence through counseling and rehabilitation. For example, in March 2023, the National Drugs Library, an Ireland-based data collection organization, reported that in 2022, the average alcohol consumption among individuals aged 15 and older increased to 10.2 liters of pure alcohol per capita, reflecting a 7.6% rise from 2021. This increase in alcohol consumption is contributing to the growth of the liver cirrhosis market.

Companies in the liver cirrhosis market are focusing on new treatment advancements, such as the development of active implantable medical devices, to improve patient outcomes and expand treatment options. Active implantable medical devices are electronically powered implants designed to monitor, support, or improve organ function within the body. For example, in December 2024, Sequana Medical NV, a Belgium-based medical device company, received U.S. FDA approval for its alfapump system, the first active implantable medical device approved in the U.S. for managing recurrent or refractory ascites caused by liver cirrhosis. This breakthrough technology offers a continuous, automated solution for fluid management by transferring excess abdominal fluid to the bladder, significantly reducing the need for invasive paracentesis. The alfapump system represents a significant step forward in improving patient outcomes and quality of life, with an addressable market of around 70,000 patients in the U.S.

In September 2023, Galectin Therapeutics, a U.S.-based company specializing in liver cirrhosis treatment, partnered with HistoIndex to present their findings on liver cirrhosis at the 9th Paris NASH meeting. Through this collaboration, the two companies aim to utilize artificial intelligence to enhance the analysis of liver cirrhosis histology, providing deeper insights into disease progression and the effectiveness of treatments. HistoIndex is a Singapore-based company specializing in medical technology.

Major players in the liver cirrhosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Viatris Inc., Grifols Therapeutics LLC, Shionogi Inc., Galectin Therapeutics Inc., NGM Biopharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Akero Therapeutics Inc.

North America was the largest region in the liver cirrhosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the liver cirrhosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liver cirrhosis is a progressive condition where healthy liver tissue is gradually replaced by scar tissue, impairing the liver's ability to function effectively. This disease results from prolonged liver damage caused by factors such as chronic alcohol consumption, viral hepatitis, or fatty liver disease.

The main types of liver cirrhosis include alcoholic cirrhosis, atrophic cirrhosis, biliary cirrhosis, cardiac cirrhosis, and cryptogenic cirrhosis. Alcoholic cirrhosis is a severe form of liver disease caused by long-term excessive alcohol consumption, which leads to liver scarring, dysfunction, and potential liver failure. Various treatment options are available, including antibiotics, immunosuppressants, and other therapies. Key end users of these treatments include hospitals, specialty clinics, ambulatory surgical centers, academic and research institutes, among others.

The liver cirrhosis market research report is one of a series of new reports that provides liver cirrhosis market statistics, including the liver cirrhosis industry global market size, regional shares, competitors with the liver cirrhosis market share, detailed liver cirrhosis market segments, market trends, and opportunities, and any further data you may need to thrive in the liver cirrhosis industry. This liver cirrhosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The liver cirrhosis market consists of revenues earned by entities providing services such as diagnosis and screening services, medical treatment, management services, and patient support. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cirrhosis market also includes sales of medications, diagnostic tools, medical devices, and therapeutic treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.